Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Karyopharm has reported positive top-line Phase IIb data from the STORM study showing the potential benefits of its orally active lead compound, selinexor, in "penta-refractory" multiple myeloma, and is aiming for rapid approval of the first-in-class agent in the US and Europe.
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.